Introduction
Materials and methods
Results
rhBMP | Authors | Study | No of patients | Delivery | Dose | Commercial name | Site | F-up | Result | Adverse events |
---|---|---|---|---|---|---|---|---|---|---|
rhBMP-2 | Govender 2002 [12] | RCT | 150 pts. IM 151 pts. IM + low dose rhBMP-2 149 pts. IM + high dose rhBMP-2 | ACS | 0.75 mg/ml Vs 1.5 mg/ml | Inductos® | Tibia | 12 m | + For high dose | None |
Jones 2006 [23] | RCT | 15 pts. ABG 15 pts. allograft + rhBMP-2 | ACS | 1.5 mg/ml | Infuse® | Tibia | 12 m | + | None | |
Swiontkowski 2006 [16] | RCT | 131 pts. Gustilo-Anderson III (66 + rhBMP-2) 113 pts. IM (65 + rhBMP-2) | ACS | 1.5 mg/ml | Infuse® | Tibia | 12 m | + | None | |
Schwartz 2008 [24] | Case report | 1 pt. rhBMP-2 + Mastergraft® | ACS | 1.5 mg/ml | Infuse® | Ulna | 22 m | + | None | |
Boraiah 2009 [25] | Comparative study | 23 pts. allograft 17 pts. allograft + rhBMP-2 | ACS | 1.5 mg/ml | Infuse® | Tibia | 18 m | − | Heterotopic bone formation in rhBMP-2 group (10/17) | |
Aro 2011 [26] | RCT | 136 pts. IM 139 pts. IM + rhBMP-2 | ACS | 1.5 mg/ml | Infuse® | Tibia | 5 m | = | More infections (19%) in rhBMP-2 Other complications peripheral oedema (26%), heterotopic ossification (26%), pain (63%) | |
Capo 2011 [27] | Case report | 1 pt ABG + rhBMP-2 | ACS | 1.5 mg/ml | Infuse® | Radius and Ulna | 9 m | + | None | |
Baltzer 2012 [28] | Case report | 1 pt. rhBMP-2 injection | None | 2 mg/ml | Inductos® | Femoral neck | 2 m | + | None | |
Julka 2012 [29] | Case report | 1 pt. rhBMP-2 | ACS | 1.5 mg/ml | Infuse® | Humerus | 4–5 m | + | Heterotopic bone formation, secondary vein compression, massive inflammatory reaction | |
Lyon 2013 [30] | RCT | 62 pts. IM 122 pts. IM + low dose rhBMP-2 125 pts. IM + high dose rhBMP-2 60 pts. IM + buffer | CPM | 1 mg/ml Vs 2 mg/ml | N/A | Tibia | 13 m | − | Severe-treatment adverse events more frequently in rhBMP group (25%) | |
rhBMP-7 | Maniscalco 2002 [31] | RCT | 7 pts. EF 7 pts. EF + rhBMP-7 | ACS | 3.3 mg/ml | OP-1 Stryker | Tibia | 6 m | = | None |
Mc Kee 2005 [32] | RCT | 62 pts. IM 62 pts. IM + rhBMP-7 | ACS | N/A | N/A | Tibia | 6 m | + | None | |
Risitiniemi 2007 [33] | Comparative study | 20 pts. EF 20 pts. EF + rhBMP-7 | Coll I powder | 3.3 mg/ml | Osigraft® | Tibia | 20 m | + | Heterotopic ossification in rhBMP group, no symptoms | |
2 and 7 | Axelrad 2008 [34] | Case series | 3 pts. rhBMP-7 + thrombin pouch 1 pt. rhBMP-2 | Coll I Powder and ACS | 3.3 mg/ml rhBMP-7 1.5 mg/ml rhBMP-2 | Infuse® OP-1 Stryker | Humerus | 6–12 m | − | 4/4 pts. developed heterotopic bone formation |
rhBMP | Authors | Study | No of patients | Delivery | Dose | Commercial name | Site | F-up | Result | Adverse events |
---|---|---|---|---|---|---|---|---|---|---|
rhBMP-2 | Crawford 2009 [35] | Case series | 9 pts. rhBMP-2 | N/A | N/A | N/A | Humerus | N/A | + | None |
Tressler 2011 [36] | Comparative study | 74 pts. ABG 19 pts. allograft + rhBMP-2 | ACS | 12 mg/cm2
| Infuse® | Multiple locations | 20 m | + | None | |
Desai 2010 [37] | Case series | 9 pts. ABG + rhBMP-2 | ACS | 1.5 mg/ml | Infuse® | Tibia | 5 m | + | None | |
rhBMP-7 | Friedlaender 2001 [14] | RCT | 61 pts. ABG 61 pts. rhBMP −7 | Coll I powder | 3.3 mg/ml | OP-1 Stryker | Tibia | 24 m | + | Higher rate of osteomielytis in ABG group (13/61) |
Pecina 2003 [38] | Case report | 1 pt. rhBMP-7 + BMAC | Coll I powder | 3.3 mg/ml | OP-1 Stryker | Tibia | 18 m | + | None | |
Kujala 2004 [39] | Case series | 5 pts. coral frame + rhBMP-2 (autografts if required) | Collagen carrier | 2–5 mg/cm3
| None | Ulna | 14 m | + | None | |
Giannoudis 2005 [15] | Case series | 395 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | OP-1 Stryker | Multiple locations | 15.3 m | + | None | |
Bong 2005 [40] | Case series | 23 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | Osigraft® | Humerus | 9 m | + | 1/23 pts. heterotopic ossification and nerve complications | |
Dimitriou 2005 [41] | Case series | 25 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | OP-1 Stryker | Multiple locations | 15.3 m | + | None | |
Calori 2006 [42] | RCT | 16 pts. rhBMP-7 13 pts. PRP | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 18.8 m | + | None | |
Ronga 2006 [43] | Case series | 105 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 29.2 m | + | None | |
Wysocki 2007 [44] | Case report | 1 pt. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | OP-1 Stryker | Humerus | 2 m | – | Heterotopic ossification of the triceps muscles | |
Kanakaris 2008 [45] | Case series | 68 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | Osigraft® | Tibia | 18 m | + | None | |
Desmyter 2008 [46] | Case series | 62 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | OP-1 Stryker | Tibia | 12 m | + | None | |
Calori 2008 [13] | RCT | 60 pts. rhBMP-7 60 pts. PRP | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 12 m | + | None | |
Giannoudis 2009 [47] | Case series | 45 pts. ABG + rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 24 m | + | None | |
Zimmermann 2009 [48] | Comparative study | 82 pts. ABG 26 pts. rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Tibia | 12 m | + | None | |
Kanakaris 2009 [49] | Case series | 30 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | Osigraft® | Femur | 24 m | + | None | |
Moghaddam 2010 [50] | Case series | 54 pts. rhBMP-7 (autografts if required) | ACS | 3.5 mg/ml | Osigraft® | Multiple locations | 6 m | + | None | |
O’hEireamhoin 2011 [51] | Case series | 13 pts. rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 9 m | + | None | |
Papanna 2012 [52] | Case series | 52 pts. rhBMP-7 (autografts if required) | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 12 m | + | 1/52 pts. developed distal tibiofibular synostosis | |
Murena 2014 [53] | Case report | 2 pts. allograft +BMAC + rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Humerus | 12 m | + | None | |
Calori 2015 [54] | Comparative study | 44 pts. ABG 44 pts. rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Multiple locations | 9 m | + | None | |
Ollivier 2015 [55] | Case series | 20 pts. rCPBS + rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Tibia | 14 m | + | 1/24 infection | |
2 vs 7 | Conway 2014 [56] | Comparative study | 112 pts. ABG + rhBMP-2 63 pts. ABG + rhBMP-7 | Coll I powder and ACS | 1.5 mg/ml 3.3 mg/ml | Infuse® Osigraft® | Multiple locations | 32 m | BMP-2 > 7 | None |
rhBMP | Authors | Study | No of patients | Delivery | Dose | Commercial name | Site | F-up | Result | Adverse events |
---|---|---|---|---|---|---|---|---|---|---|
rhBMP-2 | Sun 2014 [17] | Comparative study | 26 pts. IBG 20 pts. IBG + rhBMP-2 | N/A | 1.50 mg/ml | N/A | Femoral head | 6.1 y | = | None |
rhBMP-7 | Lieberman 2004 [57] | Case series | 15 pts. allograft + NCP + rhBMP-7 | Gelatin capsule | 50 mg | None | Femoral head | 53 m | + | None |
Marsell 2014 [58] | Case report | 1 pt. ABG + rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Humeral capitulum | 4 m | + | None | |
Papanagiotu 2014 [59] | Case series | 7 pts. AFG + rhBMP-7 | Coll I powder | 3.5 mg/ml | Osigraft® | Femoral head | 48 m | + | 4/7 developed heterotopic ossification |